MX2022012952A - Inhibidor de ret cristalino. - Google Patents

Inhibidor de ret cristalino.

Info

Publication number
MX2022012952A
MX2022012952A MX2022012952A MX2022012952A MX2022012952A MX 2022012952 A MX2022012952 A MX 2022012952A MX 2022012952 A MX2022012952 A MX 2022012952A MX 2022012952 A MX2022012952 A MX 2022012952A MX 2022012952 A MX2022012952 A MX 2022012952A
Authority
MX
Mexico
Prior art keywords
crystalline
ret inhibitor
ret
crystalline form
diseases
Prior art date
Application number
MX2022012952A
Other languages
English (en)
Inventor
Jon Gordon Selbo
Rajni Miglani Bhardwaj
Mark Steven Kerr
Douglas Patton Kjell
Jeremy Miles Merritt
Shekhar Krishna Viswanath
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of MX2022012952A publication Critical patent/MX2022012952A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Semiconductor Lasers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En el presente documento se proporciona una forma cristalina de selpercatinib útil en el tratamiento y prevención de enfermedades que pueden tratarse con un inhibidor de la quinasa RET, incluidos enfermedades y trastornos asociados con RET, y métodos para preparar esta forma cristalina.
MX2022012952A 2020-04-17 2021-04-09 Inhibidor de ret cristalino. MX2022012952A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011701P 2020-04-17 2020-04-17
US202163151354P 2021-02-19 2021-02-19
PCT/US2021/026611 WO2021211380A1 (en) 2020-04-17 2021-04-09 Crystalline ret inhibitor

Publications (1)

Publication Number Publication Date
MX2022012952A true MX2022012952A (es) 2023-01-11

Family

ID=75747118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012952A MX2022012952A (es) 2020-04-17 2021-04-09 Inhibidor de ret cristalino.

Country Status (17)

Country Link
EP (1) EP4136090A1 (es)
JP (1) JP2023522012A (es)
KR (1) KR20230002706A (es)
CN (1) CN115916791A (es)
AU (1) AU2021255488B2 (es)
BR (1) BR112022020446A2 (es)
CA (1) CA3174316A1 (es)
CL (1) CL2022002849A1 (es)
CO (1) CO2022014882A2 (es)
CR (1) CR20220520A (es)
DO (1) DOP2022000221A (es)
EC (1) ECSP22080982A (es)
IL (1) IL297212A (es)
MX (1) MX2022012952A (es)
PE (1) PE20230388A1 (es)
TW (1) TW202202501A (es)
WO (1) WO2021211380A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022069357A1 (en) * 2020-10-01 2022-04-07 Sandoz Ag Crystalline form of selpercatinib
AU2022416156A1 (en) 2021-12-13 2024-05-30 Loxo Oncology, Inc. Processes for the preparation of the crystalline form a of selpercatinib. a ret inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI791053B (zh) * 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI783057B (zh) * 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
TWI812649B (zh) * 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
US20210379056A1 (en) * 2018-09-30 2021-12-09 Applied Pharmaceutical Science, Inc. Substituted pyrazole fused ring derivative, preparation method therefor, and application thereof
CN111004257B (zh) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 制备RET抑制剂Selpercatinib的方法

Also Published As

Publication number Publication date
KR20230002706A (ko) 2023-01-05
ECSP22080982A (es) 2023-01-31
CL2022002849A1 (es) 2023-06-16
AU2021255488A1 (en) 2022-11-10
IL297212A (en) 2022-12-01
JP2023522012A (ja) 2023-05-26
AU2021255488B2 (en) 2024-05-30
CA3174316A1 (en) 2021-10-21
CR20220520A (es) 2022-11-15
BR112022020446A2 (pt) 2022-11-29
DOP2022000221A (es) 2023-01-15
PE20230388A1 (es) 2023-03-06
TW202202501A (zh) 2022-01-16
EP4136090A1 (en) 2023-02-22
CN115916791A (zh) 2023-04-04
CO2022014882A2 (es) 2022-10-31
WO2021211380A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
PH12021500017A1 (en) Pyrazolo [3,4-b]pyridine compounds as inhibitors of tam and met kinases
MX2022012952A (es) Inhibidor de ret cristalino.
MX2018000577A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa.
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
IL287032A (en) Preparations and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with disease-causing microorganisms
IL286636A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2021007260A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales.
MX2021011488A (es) Compuestos y usos de estos.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2023008968A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
MX2020009942A (es) Compuestos y usos de los mismos.
WO2023081830A3 (en) Compositions and treatments with nirogacestat
CR20210364A (es) Compuestos de quinolina como inhibidores de quinasas tam y met
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
NZ772236A (en) Pharmaceutical combination for use in age-related and/or degenerative diseases
MX2021008903A (es) Compuestos y usos de los mismos.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
MX2022010456A (es) Compuestos heterocíclicos para modular la subfamilia de receptores nucleares 2, grupo f, miembro 6.
MX2021003992A (es) Inhibidores de la acido graso sintasa (fasn).